Concepedia

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

Deniz Tural, Şebnem Batur, Sibel Erdamar, Emre Akar, Nuray Kepil, Nil Molinas Mandel, Süheyla Serdengeçti

Tumor Biology · 2013 · 31 citations · 15 references

DOI

References

15

Cancer Statistics, 2009

Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2009 · 9.7K citations · Full text

, , +18

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine · 2004 · 5K citations · Full text

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.8K citations · Full text

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker et al. · New England Journal of Medicine · 2008 · 3.6K citations

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

, , +5